| Objective:Theprimary aim of this randomized double blind controlled trial is to evaluate the efficacy of Qidi Buyuan Decoction combined with CapeOX chemotherapy on patients with liver-yin and kidney–Yin deficiency after colon cancer surgery.The main observing target as serum tumor markers in patients,immune function,quality of life and the toxic were observed to providetheoretical basis for clinical.Methods:Patients with Staging II colon cancer surgery were treated at First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine.A total of60 Patients were randomized between Oralling Chinese Medicine Decoction30 and control group 30.The control group was treated with CapeOX(oxaliplatin 130mg/m2,intravenous infusion for 2 hours,administration on the first day;capecitabine 1000mg/m2,oral administration,2 times/day,1-14 days,21 days as a cycle);The treatment group was treated with Qidi Buyuan Decoction on the basis of the control group.Each 21 days was a cycle,and four chemotherapy cycles were observed continuously.Serum tumor markers of the two groups were observed before and after treatment.The changes of tumor markers including:CEA and CA19-9,immune index containg:CD3~+,CD4~+,CD8~+and CD4~+/CD8~+,KPS score and safety index were analyzed by SPSS21.0.Results:1.The levels of markers CEA and CA19-9 in the two groups were lower than those before treatment,and the difference was statistically significant.There was no significant difference between the treatment group and the control group before and after treatment.2.CD3~+,CD4~+,CD4~+/CD8~+in the treatment group were higher than those in the control group,and CD8~+in the treatment group was lower than those in the control group.CD3~+,CD4~+,CD4~+/CD8~+in the control group were lower than those in the control group after treatment,with significant difference,and CD8~+in the control group was higher than that in the control group.There was no significant difference in self-comparison before and after treatment in the treatment group.3.The KPS score of the treatment group was higher than that of the control group.There was no significant difference in the KPS score of the control group before and after treatment.After treatment,the KPS score of the treatment group was higher than that before treatment,and the difference was statistically significant.4.There was no significant difference between the two groups in liver and kidney function injury and peripheral nerve injury.After treatment,the incidence of hemoglobin reduction in the treatment group 25.00%was lower than that in the control group 50.00%.The difference was statistically significant.The incidence of nausea-vomiting aup.Conclusion:1.Qidi Buyuan Decoction combined with CapeOX chemotherapy can reduce the levels of serum tumor markers CEA and CA19-9 in patients with liver-yin and kidney-Yin deficiency after colon cancer surgery.2.Qidi Buyuan Decoction combined with CapeOX chemotherapy can maintain the levels of CD3~+,CD4~+,CD8~+,CD4~+/CD8~+in patients with liver-yin and kidney-Yin deficiency after colon cancer surgery.3.Qidi Buyuan Decoction combined with CapeOX chemotherapy can improve the quality of life of patients with liver-yin and kidney-Yin deficiency after colon cancer surgery.4.Qidi Buyuan Decoction combined with CapeOX chemotherapy can reduce the alleviatethe toxicity of chemotherapy. |
PDF Full Text Request